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Methicillin-resistant Staphylococcus aureus: Vascular
Surgeons Should Fight Back
J. J. Earnshaw
Gloucestershire Vascular Group, Gloucestershire Royal Hospital, U.K.
Methicillin-resistant Staphylococcus aureus (MRSA) is now the commonest cause of serious vascular wound and graft
infection in the U.K., and vascular departments in many other countries are similarly affected. There are no randomised
trials that provide information about how to deal with this epidemic. There are, however, a number of clinical series that
provide data that can be used to mount a logical and coherent response to the problem of preventing and managing MRSA
infection. The risks and problems are different in every hospital and co-operation with local microbiologists is essential in
creating individual protocols. Stratifying the risk to each patient is the first step; established antiseptic and surgical
procedures are usually adequate as primary prevention. Studies into the role of targeted antibiotic therapy and isolation
techniques are needed.
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Vascular surgeons have adapted their practice to take
into account the threat of wound and graft infection.
Scientific studies have established the role of various
prophylactic manoeuvres to minimise the risk of
infection, yet graft infection still occurs at a rate of
3±5%.1 In the last 8 years an epidemic of methicillin
resistant Staphylococcus aureus (MRSA) infection has
run rife through many hospitals and in many coun-
tries. It affects precisely the patients that vas-
cular surgeons are called to treat: the elderly, the
debilitated and those with ulcers, gangrene and
chronic sepsis.
It is time for vascular surgeons to mount a coherent
response in the battle against MRSA. Modern thera-
pies rely on evidence from randomised clinical trials,
but none exists. The only way to develop a strategy is
to learn from the available studies and then add a large
dose of common sense.Please address all correspondence to: J. J. Earnshaw, Gloucestershire
Vascular Group, Gloucestershire Royal Hospital, Great Western
Road, Gloucester GL1 3NN, U.K.
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A number of reviews have illustrated the effects of
MRSA on vascular surgical practice.2±5 In the United
Kingdom (U.K.), there is evidence from the Public
Health Laboratory Service that MRSA is causing an
increasing number of infections,6 peripheral vascular
surgery and amputation are among the areas most
affected (Fig. 1). Several large reviews from hospitals
in the U.K. support this increase.2±4 Most studies come
from inner city teaching hospitals and it might be
speculated that these high volume centres are the
ones most at risk. The increasing incidence is paral-
leled by rising morbidity and mortality: patients with
MRSA infection of a prosthetic infra-inguinal bypass
graft have a high incidence of amputation,3,4 MRSA
aortic graft infection seems almost universally lethal,3
and unusually, MRSA seems capable of causing
primary infection of a native artery.3 A multicentre
survey done in 2000 by the Joint Vascular Research
Group showed that MRSA was the current leading
cause of vascular graft infection in the U.K. Patients
with MRSA had a higher major amputation rate and
prolonged hospital stay compared with other graft
infections, however, mortality was not increased.5l rights reserved.
Fig. 1. Data from surveillance of surgical site infection in English
hospitals 1997±9 demonstrating the high incidence of Staphylococcus,
and in particular, MRSA infection in patients undergoing vascular
or amputation surgery. Available online ± www.phls.org.uk/
publications/NINSS.htm
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but review of articles from Medline suggests that there
is an increasing worldwide epidemic with this viru-
lent organism.
Preventing MRSA infection in vascular patients
requires adaptation of all the techniques vascular
surgeons have used over the years to combat post-
operative sepsis. The measures employed have to
account for the varying risks of infection among
the different vascular patients, and also the prevalence
of MRSA in each hospital. Patients vary in risk,
ranging from those who are not colonised with
MRSA having a low risk procedure (elective aortic
aneurysm repair), through those with known sepsis
and possible, but undocumented MRSA colonisation
or infection (patient admitted with gangrene from
a nursing home, or who has previously been in
hospital), to a patient with established MRSA infection
who needs a vascular surgical procedure. DealingEur J Vasc Endovasc Surg Vol 24, October 2002with each of these categories requires variation on
the same procedures.
Preoperative Measures
In a hospital with a low prevalence of MRSA, little
needs to be done other than normal prophylaxis
against infection. In a high prevalence hospital it
makes sense to separate low risk patients preopera-
tively from those known to have, or be at risk of
MRSA colonisation. Patients having elective aortic
surgery or bypass for claudication should be admitted
on the day of operation and into clean wards/bays. In
a high prevalence hospital it is logical to keep patients
at home as long as possible up until the day of surgery
so that they cannot become colonised, particularly if
they have an open ulcer or gangrene.
Patients with ischaemic rest pain, gangrene or
ulcers are likely to have skin colonisation with
bacteria (possibly including MRSA). The identification
of MRSA colonisation/infection is important and
many surgeons screen moderate or high risk patients
either before, or as soon as they are admitted to
hospital; patients admitted as an emergency out of
hours must not be allowed to escape the system.
Although it has not been possible in a randomised
trial to show that reducing the bacterial load with
bathing reduces the rate of wound or graft infection,7
many surgeons employ preoperative antiseptic baths
to try and cleanse the skin (chlorhexidine or triclosan
are appropriate).
Patients with established MRSA infection are at
high risk of infective complications after vascular
reconstruction. There may be time to attempt to eradi-
cate the infection before surgery but this is rarely
possible in patients with established skin necrosis.
Judicious debridement, use of systemic antibiotics
for cellulitis or topical antibacterials (mupirocin) for
infected open ulcers may reduce the bacterial load.
Early reports suggest that debridement with larval
therapy may be a way to eradicate MRSA.8 Finally
it may be appropriate to review the indication for
vascular reconstruction; occasionally it may be
possible to do a long subintimal angioplasty instead
of a femorodistal bypass. Whilst vascular surgeons
rarely like to admit defeat when a reconstruction is
technically possible, in a patient with gangrene whose
only hope is a high risk, distal prosthetic bypass, the
risks of the reconstruction may outweigh the dis-
advantages of primary amputation. In this circum-
stance, MRSA may shift the balance of therapy
against vascular reconstruction. In the modern era,
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shared with the patients and their relatives.
Operative Measures
Whilst the use of autologous material for reconstruc-
tion is not a total protection against sepsis, clearly the
important principle is that prosthetic material should
seldom be employed in patients known, or suspected
to have MRSA infection. Whereas this is not a new
message for patients undergoing femorodistal bypass
surgery, for other reconstructions greater ingenuity
may be required; deep femoral vein is an alternative
in patients who need an aortoiliac reconstruction.
When conventional reconstruction is employed,
standard surgical procedures such as oblique skin
incisions in the groin and skin bridges in the thigh
have been shown to reduce the rate of infection.9 The
development of antibiotic impregnated vascular grafts
heralded much promise but it has not been possible to
confirm their potential in randomised studies, and
there is some evidence that rifampicin, the most
commonly employed antibiotic, is relatively ineffec-
tive against MRSA.10
Most vascular graft infection is caused by implanta-
tion of bacteria at the time of vascular reconstruction.
Therefore, prevention of contamination at operation is
important. Whilst none of the available measures has
basis in scientific trials, many surgeons employ occlu-
sive wound drapes, antiseptic or antibiotic wound
lavage, or implantation of antibiotic coated vehicles
such as gentamicin collagen swabs or gentamicin
beads. At least none of these measures has proved
harmful.11 One other way to reduce late recolonisation
is to remove all infected or necrotic tissue at the end of
the reconstruction operation.
Antibiotic prophylaxis is the one measure clearly
shown to reduce the risk of wound, though not graft
infection.1,9 None of the available randomised trials
studied MRSA infection specifically. Antibiotics effec-
tive against MRSA include teicoplanin, vancomycin
and linezolid. Vancomycin is cheapest but the most
toxic. Teicoplanin is safer but more expensive. Linezo-
lid has the advantage that it is equally well absorbed
orally as parenterally, however, the cost of the tablets
is the same as the parenteral drug. All patients having
a vascular reconstruction should receive antibiotic
prophylaxis; those at risk of, or with established
MRSA infection should have an antibiotic effective
against MRSA included. Two studies in vascular
surgical patients used teicoplanin, though neither
trial was sufficiently powered to show a statisticallysignificant benefit.12,13 Each vascular unit should
create its own protocol for antibiotic prophylaxis. This
process should include local knowledge of the types
and prevalence of MRSA infection and is facilitated by
advice from a microbiologist. Whereas targeted pro-
phylaxis is not indicated in low prevalence vascular
units, it can be argued that patients with established
MRSA infection should have a longer course of peri-
operative antibiotics than the standard one to three
doses. New trials of antibiotic prophylaxis in high
prevalence vascular units would be very helpful.
Postoperative Measures
It is unlikely that much can be achieved by varying
postoperative care. Low risk patients should avoid
contact with MRSA patients soon after surgery.
A recent study documented that patients continue to
pick up MRSA during their postoperative stay in ITU
and back on the ward.14 Dressings probably do not
affect the outcome for a wound, though in high risk
patients covering the wounds with an antibacterial
dressing might help. Any wound infection should be
treated promptly with help from a microbiologist. The
lessons learned from the open clinical studies are that
bold remedial surgery is less likely to be effective in a
patient with deep MRSA wound or graft infection.2±4
Revision therapy should include excision of all
infected and necrotic material with recourse directly
to major limb amputation, if necessary.
The Role of Isolation
Some hospitals practice isolation of patients with
MRSA. This can only be done if facilities are available
and if the burden of patients in a particular hospital is
not too great; MRSA is endemic in many hospitals in
the U.K. Isolation can reduce the opportunity for
transmission of MRSA and was effective at St Mary's
Hospital in reducing the rate of graft infection.4 Trans-
mission of MRSA can be minimised by isolating
patients known to be colonised or infected with
MRSA, but the availability of isolation rooms (usually
side rooms off the main ward ± few hospitals have an
isolation unit) has long ago been outstripped by the
number of colonised patients.
Nosocomial acquisition can be reduced by strict
attention to handwashing and the appropriate use of
other isolation nursing techniques such as wearing an
apron, correct handling of linen and dressings. TheEur J Vasc Endovasc Surg Vol 24, October 2002
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staff for nasal or skin carriage can be applied in high
risk areas of the hospital, which may include the
vascular unit.15 An alternative might be to create
MRSA-free areas where patients having clean surgery
may be housed.
Opinion is divided on whether attempts should be
made to eradicate MRSA from clinical areas. Some
North European countries have kept the infection
under control with elimination and infection control
policies.16
Conclusions
There are a number of simple measures that vascular
surgeons can employ that might reduce the risk of
MRSA infection. Just how much to do depends on
the prevalence of MRSA in the individual unit. The
first imperative is that vascular surgeons should take
stock of the situation in their hospitals and agree
a local response. This will require close collaboration
with the hospital's microbiologists. Together, written
protocols should be produced for dealing with each
category of patient (low risk/high risk/known MRSA),
including antibiotic prophylaxis. Junior staff should
be trained to grade patients into risk categories on
admission, just as they do for risk of deep vein throm-
bosis, as part of a care plan. Perhaps using this
common sense approach, the MRSA epidemic in
vascular patients could be controlled without waiting
for the results of scientific studies.
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